Colorectal cancer (CRC) is the third most common tumor in men and the second most common tumor in women. Aflibercept is a recombinant fusion protein that has part of the human VEGF receptors 1-2 fused to the Fc portion of human IgG1. It is designed to act as a high-affinity
soluble decoy receptor that provide blockade of the VEGF pathway by preferentially binding to VEGF-A, VEGF-B and PIGF. The VELOUR trial tested second-line aflibercept in patients with mCRC that progressed after one regimen containing oxaliplatin. The trial met its primary endpoint with an improvement in OS. However, the prognosis during second-line therapy is heterogeneous, and multiple factors converge to additively modulate OS. The V-TRAP model can be useful to inform about prognosis, patient counseling, stratification in clinical trials, or healthcare decision making.